- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02730845
Intra-articular Versus Intravenous Dexmedetomidine in Arthroscopic Knee Surgeries Under Local Anesthesia
Intra-articular Versus Intravenous Administration of Dexmedetomidine in Arthroscopic Knee Surgeries: A Prospective Randomized Study
The present study will be carried to evaluate the efficacy of intra-articular 0.5 bupivacaine with intra-articular or intravenous alpha-2agonist; Dexmedetomidine; for intraoperative anesthesia and postoperative analgesia after arthroscopic knee surgery.
Arthroscopic knee surgery is one of the most common minimally invasive orthopedic procedures in recent practice which is frequently performed as a day surgery procedures. It can be done under general, regional or local anesthesia (LA) with or without sedation. It is associated with varying amount of postoperative pain. Postoperative pain negatively influences patient's early ambulation, rehabilitation and psychology which consecutively prolonged the hospital stay.
Intra-articular administration of local anesthetic for knee arthroscopy is a well-documented procedure that offers many advantages over other anesthesia types. Many anesthesiologists are still trying to improve the technique of local anesthetic administration through using many combinations with LA solutions in order to administer safe anesthesia to those patients and to obtain a pain-free knee with good operating conditions.
Dexmedetomidine is a highly selective α2 adrenergic agonist. It has analgesic, sedative, anxiolytic, hypnotic, sympatholytic, antihypertensive properties with anesthetic sparing effects. It becomes an attractive alternative to the current opioids because it does not have a respiratory depressant or addictive effect.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients were kept fasting after midnight and received midazolam 5 mg orally as premedication. All patients were premedicated with I.V. midazolam 0.03 mg/kg ten minutes before starting the operation. The anesthetic technique was standardized for all patients. All surgical procedures were performed by the same surgeon and consisted of arthroscopic removal of torn meniscus. Both intra-articular and intravenous solutions were prepared by an individual not involved in the study and the intra-articular drugs were injected by the surgeon (without knowing the contents). The anesthesiologist managing and monitoring the patient throughout the surgery provides IV drugs. No leg holder or tourniquet or surgical drain was used for any of the cases. After preparation and draping the patient's leg, patients were warned prior to each needle stick to decrease anxiety. All procedures were performed under complete aseptic conditions. Skin and subcutaneous tissues at each arthroscopic portal site were anesthetized with LA consisting of injection of a mixture of 2% lidocaine 5 mL with 1:200,000 epinephrine.
Care should be taken to avoid infiltration of the fat pad. It is a relatively aneural structure; as, too much local infiltration allows it to bulge out into the joint during the surgery. Flexion and extension of the knee joint several times help to spread of intra-articular solution and then waiting 20 minutes for anesthesia to take effect is helpful before the surgical incision.
The arthroscope was inserted into the knee, and inflow through the sheath was established. No pump was used for the saline inflow which was maintained through the arthroscope by the gravity. Gravity outflow drained through the superolateral portal. A separate egress cannula was used if indicated. The patient was encouraged to view the video monitor during the procedure. Constant verbal communication between the surgeon and the patient is important throughout the arthroscopic examination and surgery. This keeps the patient anxiety and muscle tension to the minimum which facilitates manipulation of the leg and thorough examination of the entire joint. Once finishing, instruments were removed and portals were closed with a 4-0 absorbable suture subcutaneously and steri-strips. A compression dressing was applied for three days to the knee.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
DK
-
Mansoura, DK, Egypt, 050
- Mansoura University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anesthesiologists physical status I or II
- Patients scheduled for elective unilateral knee arthroscopy
Exclusion Criteria:
- Refusal of local anesthesia
- History of cardiovascular disease
- History of cerebrovascular disease
- History of respiratory diseases
- History of impaired renal functions
- History of impaired hepatic functions
- Pregnancy
- Allergy to the study drugs
- Uncontrolled diabetes
- Coagulopathies
- Hypertension treated with α methyldopa, clonidine or β adrenergic blockers
- Patients receiving chronic pain treatment
- Patients receiving psychoactive drugs
- Patients receiving anticoagulant drugs
- Prior ipsilateral knee surgery
- Infection at site of injection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Intra-articular dexmedetomidine
Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
|
Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000
added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v.
saline 20 ml infused over 10 min starting with local anesthesia
|
PLACEBO_COMPARATOR: Intravenous dexmedetomidine
patients will be subjected for elective knee arthroscopy under local anesthesia (i.v.
dexmedetomidine + Intra-articular bupivacaine).
|
Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000
and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v.
20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain scores
Time Frame: for 24 hours starting immediately before performing the procedure
|
Pain will be assessed using 10 cm visual analogue scale (VAS)
|
for 24 hours starting immediately before performing the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart rate
Time Frame: starting immediately before performing the procedure
|
starting immediately before performing the procedure
|
|
Blood pressure
Time Frame: starting immediately before performing the procedure
|
Changes in systolic and mean blood pressure
|
starting immediately before performing the procedure
|
Oxygen saturation
Time Frame: starting immediately before performing the procedure
|
Changes in peripheral oxygen saturation
|
starting immediately before performing the procedure
|
Respiratory rate
Time Frame: starting immediately before performing the procedure
|
Changes in respiratory rates will be recorded
|
starting immediately before performing the procedure
|
Level of sedation
Time Frame: For 24 hours after performing the injection
|
will be evaluated using the following scale: (5= awake/alert to 0= asleep/unarousable )
|
For 24 hours after performing the injection
|
Patient Satisfaction Score
Time Frame: For 24 hours after performing the procedure
|
will be assessed using the following scale: 5= very satisfied, 4= satisfied, 3 = neutral, 2 = dissatisfied, 1 = very dissatisfied |
For 24 hours after performing the procedure
|
Time to first postoperative analgesic requirement
Time Frame: For 24 hours after performing the injection
|
This will be recorded as the time to first postoperative analgesic requirement
|
For 24 hours after performing the injection
|
Intraoperative and postoperative side effects
Time Frame: For 24 hours after performing the injection
|
These include nausea, vomiting, hypotension, bradycardia, respiratory depression, Hypertension
|
For 24 hours after performing the injection
|
Time to mobilization out of bed
Time Frame: For 48 hours after performing the procedure
|
will be recorded in minutes from skin closure
|
For 48 hours after performing the procedure
|
Post-anesthesia care unit (PACU) length of stay
Time Frame: For 4 hours after surgery
|
will be recorded from time between transfer from the operating room to PACU and discharge
|
For 4 hours after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tarek H Ramadan, MD, Lecturer of anesthesia and surgical intensive care
- Study Director: Reem A AbdelRaouf, MD, Lecturer of anesthesia and surgical intensive care
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- R∕ 15.10.40
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Arthroscopy
-
University Hospital, Strasbourg, FranceRecruiting
-
Peking University Third HospitalCompleted
-
Sheba Medical CenterWithdrawn
-
The Cleveland ClinicTerminatedKnee ArthroscopyUnited States
-
Hospital for Special Surgery, New YorkTerminated
-
Centre Hospitalier Universitaire Saint PierreHôpital de Braine-l'AlleudCompleted
-
University Health Network, TorontoCompleted
-
Huazhong University of Science and TechnologyCompletedKnee Arthroscopy SurgeryChina
-
Orthopaedic Research and Innovation Foundation,...Completed
Clinical Trials on Intra-articular dexmedetomidine
-
Istanbul UniversityRecruiting
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
Seoul National University HospitalCompletedAdhesive CapsulitisKorea, Republic of
-
Istituto Ortopedico RizzoliCompleted
-
Xuanwu Hospital, BeijingNot yet recruitingAtlantoaxial Dislocation
-
LabrhaStatitecCompletedKnee OsteoarthritisFrance
-
St George's, University of LondonWellcome Trust; Rosetrees TrustUnknownRheumatoid Arthritis | Osteoarthritis, Knee | Psoriatic Arthritis | SpondyloarthritisUnited Kingdom
-
Sisli Hamidiye Etfal Training and Research HospitalCompleted
-
University Hospital TuebingenUnknownJuvenile Idiopathic ArthritisGermany
-
Procare Health Iberia S.L.Active, not recruitingOsteoarthritis, Hip | Osteoarthritis Thumb | Osteoarthritis AnkleSpain